Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for UNITED THERAPEUTICS (UTHR) over the last 14 years, with Sep 2025 value amounting to $8.4 million.

  • UNITED THERAPEUTICS's Gains from Investment Securities fell 89.13% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.6 million, marking a year-over-year decrease of 3.19%. This contributed to the annual value of $400.6 million for FY2024, which is 20.48% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Gains from Investment Securities stood at $8.4 million, which was down 96.48% from $238.6 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Gains from Investment Securities ranged from a high of $238.6 million in Q2 2025 and a low of $2.3 million during Q2 2021.
  • Its 3-year average for Gains from Investment Securities is $85.9 million, with a median of $77.3 million in 2024.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Gains from Investment Securities slumped by 89.15% in 2021 and then surged by 273.28% in 2022.
  • UNITED THERAPEUTICS's Gains from Investment Securities (Quarterly) stood at $23.2 million in 2021, then surged by 273.28% to $86.6 million in 2022, then increased by 11.55% to $96.6 million in 2023, then increased by 15.22% to $111.3 million in 2024, then tumbled by 89.13% to $8.4 million in 2025.
  • Its Gains from Investment Securities was $8.4 million in Q3 2025, compared to $238.6 million in Q2 2025 and $15.3 million in Q1 2025.